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S U M M A R Y
Objective: To analyze the recent epidemiology of methicillin-resistant Staphylococcus aureus (MRSA)
bacteremia in a UK tertiary referral center.
Methods: We collected epidemiological and laboratory data on all cases of MRSA bacteremia from
September 1, 2005 to December 31, 2007.
Results: There were 195 clinically signiﬁcant episodes. Most were hospital-acquired. Only one episode
occurred in patients without a history of hospital admission in the previous 12 months. An intravascular
device was the most common focus of infection (37%), with no identiﬁable source found in 35% of
episodes. Twenty-eight percent of patients died within 30 days of bacteremia. Mortality was
signiﬁcantly higher in the absence of an identiﬁable focus. Failure to include an antibiotic active against
MRSA in the empirical treatment was only signiﬁcantly associated with death in patients showing signs
of hemodynamic instability (p < 0.001). No isolates had a minimum inhibitory concentration to
vancomycin above 1.5 mg/l and no heteroresistance to glycopeptide antibiotics (heteroresistant
vancomycin-intermediate Staphylococcus aureus; hVISA) was detected. All isolates were sensitive to
daptomycin, tigecycline, and linezolid.
Conclusions: Despite improvement in infection control measures, medical devices remain the most
common source of infection. Inappropriate empirical antibiotic usage is associatedwith a poor outcome in
patients with signs of severe sepsis. Susceptibility to glycopeptides and newer antibiotics remains good.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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While recent data have shown a signiﬁcant and sustained
reduction in hospital-acquired methicillin-resistant Staphylococcus
aureus (MRSA)bacteremia in theUK,1 it remains ahighprioritydue to
the high associatedmortality, excess healthcare costs, and increasing
concerns about unsatisfactory response to standard therapy,
particularly glycopeptides.2 Moreover, with speciﬁc strains of
community-associatedMRSA causing serious infections in previous-
lyhealthypeoplewithout risk factors, and reportsof infectionsdue to
such strains among hospitalized patients,3 there is a need for regular
surveillance of the epidemiology of serious MRSA infections.
We undertook this study to analyze the epidemiology, clinical
characteristics, andoutcomeofMRSAbacteremia.Wealso reviewed§ Presented in part at the 19th European Congress of Clinical Microbiology and
Infectious Diseases, Helsinki, Finland, May 16–19, 2009 with the title ‘‘Epidemiol-
ogy of MRSA bacteraemia and clinical relevance of reduced susceptibility to
vancomycin’’.
* Corresponding author. Tel.: +44 0 121 627 2366; fax: +44 0 121 414 1682.
E-mail address: ira.das@uhb.nhs.uk (I. Das).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.09.013the antibiotic susceptibility patterns including detection of reduced
susceptibility to vancomycin and heterogeneously expressed
vancomycin resistance (heteroresistant vancomycin-intermediate
Staphylococcus aureus; hVISA) among the MRSA isolates.
2. Methods
2.1. Clinical data collection
University Hospital Birmingham is a 1200-bed tertiary referral
hospital in the West Midlands region of the UK. Episodes of MRSA
bacteremia over a 28-month period, between September 1, 2005
and December 31, 2007, were retrospectively identiﬁed from
laboratory computer records. For each episode, laboratory records
were also searched for previous isolates of MRSA in any specimen
since January 2003, or any subsequent isolate of MRSA from blood
or other sterile site during subsequent admissions, until December
31, 2008. Clinical details of cases were retrieved from clinical
microbiology notes and from patient records. Details of antibiotic
therapy and results of relevant non-microbiological laboratory
tests were retrieved from the electronic patients information andses. Published by Elsevier Ltd. All rights reserved.
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were also retrieved through the above system. Patients were
followed up until discharge or death (during hospital admission). If
discharged within 30 days of MRSA bacteremia, we used PICS to
determine further clinical progress.
2.2. Laboratory methods
Blood cultures were processed by an automated system (Bactec
9240, Becton Dickinson Microbiology System, Sparks, MD, USA).
Identiﬁcation of MRSA and initial antibiotic sensitivity testing
were performed by the standard methods and using the Vitek 1
automated system (bioMe´rieux, France). Isolates were saved on
beads and stored at 20 8C. After recovery onto blood agar,
methicillin resistance was conﬁrmed by subculture on selective
chromogenic agar (bioMe´rieux, France). Minimum inhibitory
concentration (MIC) determinations were performed using E-test
strips according to the manufacturer’s instructions (AB Biodisk,
Sweden). Heteroresistance to vancomycin was deﬁned by the
presence of microcolonies at 8 mg/l with vancomycin and
teicoplanin, or 12 mg/l teicoplanin, using E-test strips on
brain–heart infusion (BHI) agar with a 2 MacFarland bacterial
inoculum.4 All MICs were read by a single observer who had no
knowledge of clinical outcome for any of the episodes. Mu3 and
Mu50 strains were used as controls for hVISA and VISA,
respectively.5 Assignment of SCCmec element types I–V and
subtyping of SCCmec type IV isolates were performed as previously
described.6,7
2.3. Statistical methods
Categorical variables were summarized as numbers and
percentages and ages were summarized as medians and ranges.
Fisher’s exact test was used for between-group comparisons of
categorical variables and the Mann–Whitney test was used for
comparisons of age. Logistic regression was used for multivariable
analyses. All statistical analyses were performedwith SPSS 15.0 for
Windows (SPSS Inc., Chicago, IL, USA).
2.4. Deﬁnitions
An episode of MRSA bacteremia was deﬁned as any blood
culture positivewithMRSA. Episodes occurringwithin 2weeks of a
previous one, or without resolution of signs and symptoms of
infection after a previous episode, were considered as single
episodes. A hospital-associated episode was deﬁned as one
occurring more than 48 h after admission. A healthcare-associated
episode was deﬁned as one occurring less than 48 h after
admission, but with contact with secondary or tertiary healthcare
facilities in the preceding 12 months. Other episodes were deﬁned
as community-associated.
An intravascular device (IVD) was thought the likely focus of
infection if there was evidence of inﬂammation at the catheter
insertion site and/or a catheter tip culture was positive for MRSA
by a semi-quantitative method.8 Endocarditis was deﬁned
according to themodiﬁed Duke’s criteria.9 Pneumonia was deﬁned
as the source of bacteremia in the presence of purulent sputum
from which MRSA was isolated and new lung ﬁeld opacity on
radiographic examination.
Co-morbid conditions analyzed included diabetes mellitus,
chronic heart disease, chronic lung disease, liver failure, chronic
renal disease, immunosuppression, and malignancy. Fever was
deﬁned as a single oral temperature of 38 8C. Hemodynamic
instability was deﬁned as a systolic blood pressure <90 mmHg, a
diastolic blood pressure of <60 mmHg, or ﬂuid or inotrope
requirement to maintain blood pressure above these levels. Targetvancomycin serum levels were 10–15 mg/l. Previous vancomycin
exposurewas determined from electronic records, andwas deﬁned
as being any administration of vancomycin more than 2 weeks but
less than 1 year before an episode. Empirical antibiotic therapywas
deﬁned as any antibiotic(s) prescribed on the day that the blood
culture was taken (i.e., before antimicrobial susceptibilities were
known).
2.5. Routine follow-up for cases of MRSA bacteremia
For eachMRSA bacteremia, routine advice forwork-up included
identiﬁcation of source, removal of the source if possible, and
drainage of any collections. A transthoracic echocardiogram (TTE)
was recommended if there was no clinically identiﬁable source. A
transesophageal echocardiogram (TEE) was undertaken for cases
with a strong suspicion of endocarditis but a negative or
inconclusive TTE. TEE was undertaken directly for high-risk cases,
e.g., history of previous cardiac surgery or known cardiac valvular
abnormality. A repeat blood culture was advised in any of the
following cases: clinical features of sepsis absent at the time of
initial blood culture result (to help assess the signiﬁcance of the
positive blood culture); continuing sepsis in spite of treatment
with anti-MRSA antibiotics; when infective endocarditis was
clinically suspected; underlying known cardiac valvular patholo-
gy; or history of cardiac valve surgery. Repeat blood cultures were
encouraged in other cases to determine clearance of bacteremia. A
2-week course of antibiotics was recommended for uncomplicated
bacteremia.
3. Results
3.1. Clinical picture
We identiﬁed 199 distinct episodes of MRSA bacteremia from
183 patients. In four episodes from four patients, symptoms had
resolved without antibiotics and theMRSA bacteremia was not felt
to be clinically signiﬁcant. These episodes were excluded from the
analysis, leaving a total of 195 episodes from 179 patients for
further evaluation. In all but one episode, there had been prior
contact with secondary or tertiary healthcare services in the
previous 12 months (Table 1). Twenty episodes (10%) occurred in
patients admitted to an intensive care unit. IVDs were the most
common identiﬁable source of infection (73 episodes; 37%). A
source could not be identiﬁed in 68 episodes (35%). Of these 68
episodes, 21 (11%) occurred in patients with an IVD who did not
meet the criteria for IVD infection. We did not ﬁnd any episodes
associated with pneumonia. Data on patient temperature and
blood pressure at the time of blood culture acquisition were
available for 183 (94%) episodes. Pyrexia was present in 155/183
(85%) episodes and hemodynamic instability present in 54/183
(30%) episodes.
For 68 (35%) episodes, MRSA was isolated from specimens
(including MRSA screens) prior to the positive blood cultures. For
41 (21%) episodes, there had been a negative screen for MRSA and
no isolation of MRSA during the 3-month period prior to the
positive blood cultures. For the remaining 86 (44%) episodes, no
MRSA screen was carried out during the 3-month period prior to
the positive blood culture.
3.2. Antibiotic treatment
In eight episodes a decision was made to withdraw medical
treatment and in two episodes the patients were transferred to
other institutions, and no treatment data were available. These 10
episodes have been discounted from further analyses. Of the
remaining 185 episodes, empirical antibiotics were administered
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Figure 1. The inﬂuence of empirical antibiotic choice and hemodynamic status on
mortality over the ﬁrst 6 days after drawing of blood culture. Squares: empirical
antibiotic not active against MRSA; circles: empirical antibiotic active against
MRSA; closed: patient hemodynamically stable at time of blood culture; open:
patient not hemodynamically stable at time of blood culture (see Table 2 for
numbers in each group).
Table 1
Demographic data of patients with MRSA bacteremia
All episodes (N = 195)
Median age (range), years 65 (18–100)
Female sex 73 (37%)
Any co-morbidity 152 (78%)
Acquisition
Hospital 137 (70%)
Healthcare-associated 57 (29%)
Community 1 (1%)
Previous MRSA bacteremia 22 (11%)
Prior exposure to vancomycin 42 (22%)
Source
IVD 73 (37%)
Unidentiﬁed 68 (35%)
Surgical site 16 (8%)
Skin 14 (7%)
Abscess 7 (4%)
Urinary tract 6 (3%)
Endocarditis 6 (3%)
Bone and joint 3 (2%)
No dataa 2 (1%)
Specialty
Liver 24 (12%)
Renal 42 (22%)
Hemato-oncology 18 (9%)
General medicine 47 (24%)
General surgery 31 (16%)
Other 33 (17%)
On intensive care unit 20 (10%)
30-day mortalityb 52 (28%)
Subsequent relapse 16 (8%)
Other subsequent complicationc 5 (3%)
Transfer from other hospital 25 (13%)
MRSA, methicillin-resistant Staphylococcus aureus; IVD, intravascular device.
a Incomplete notes.
b Mortality at 30 days not known for nine patients: discharged to die at home (n =
2); transfer to other centers (n = 2); probably alive – well on discharge with no co-
morbidity and not readmitted (n = 4); no data (n = 1).
c Including sternal wound infections (n = 2), neck abscess (n = 1), infected
pacemaker (n = 1), culture-negative endocarditis (n = 1).
Table 2
Inﬂuence of empirical antibiotic choice and hemodynamic status on 30-day
mortality
Hemodynamic
status
Empirical
antibiotic
Number of
episodes
All-cause
mortality
n %
Stable None/inactive against
MRSA
80 14 18
Active against MRSA 46 10 22
Unstable None/inactive against
MRSA
32 13 41
Active against MRSA 17 1 6
MRSA, methicillin-resistant Staphylococcus aureus.
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of antibiotic was active against MRSA, and included vancomycin
(60 episodes), linezolid (5 episodes), and gentamicin (1 episode).
Following a positive blood culture result, an antibiotic active
against MRSA was used in 175/185 (95%) episodes. These included:
vancomycin (163 episodes, 93%), linezolid (nine episodes), doxycy-
cline (two episodes), and gentamicin (one episode). Rifampin was
used as adjunctive therapy in 53 episodes (30%). In four episodes, no
antibiotic active against MRSA was ever prescribed as the patient
was felt to be improving without antimicrobial treatment: in three
episodes thiswas after removal of a suspected IVD source and in one
episode the patient had been discharged from hospital after trans-
urethral resection of the prostate andwas felt by the clinical team to
have improved. In the remaining six episodes, the empirical
antibiotic choice was inactive against MRSA and the patient died
before culture results were available.
3.3. Clinical outcome
Fifty-two (28%) patients died within 30 days of collection of the
positive blood culture. In univariable analysis, only failure to
identify a source of infection (odds ratio 8.24, 95% conﬁdence
limits 3.71–18.26; p < 0.001) and admission to the intensive care
unit (ICU) (odds ratio 3.68, 95% conﬁdence limits 1.40–9.67; p =
0.016) were signiﬁcantly associated with death. These variables
remained signiﬁcant (p < 0.001) in a multivariable analysis, also
adjusting for age.
Data on both hemodynamic status and antibiotic treatment
were available for 175/185 (95%) episodes (Table 2). There was a
signiﬁcant interaction effect, i.e., mortality was high in hemody-namically unstable patients who were not administered an
empirical antibiotic active against MRSA (p< 0.001), but empirical
antibiotic prescribing had no inﬂuence on mortality in patients
who did not show signs of hemodynamic instability (p = 0.025).
This effect was most notable over the ﬁrst few days after the blood
culture was taken (Figure 1).
Follow-up blood cultures were received within 7 days of the
initial MRSA bacteremia from 83 patients (46%). Eighteen of the
remaining96patients (10%of total 179) diedwithin aweekofMRSA
bacteremia, further contributing to the lack of follow-up blood
cultures within this period. There were 22 episodes (11%) of relapse
during the study period and subsequent 12months of follow-up. In
six of these episodes the initial MRSA bacteremia had occurred
before the studyperiod. Sourcesof infection in relapses included IVD
(n = 9), no identiﬁable focus (n = 5), abdominal abscess (n = 4), skin
(n = 2), lung abscess (n = 1), and discitis (n = 1). Two further patients
had persistent bacteremia, one over a period of 4 months (due to
sternal wound infection) and the other over 16 months (due to
infected pacing material). Five patients had infective complications
without apositivebloodculture. In fourpatients,MRSAwascultured
from a normally sterile site, including a neck abscess (n = 1), sternal
wound (n = 2), and pacemaker material (n = 1). One patient was
diagnosed with culture-negative endocarditis.
3.4. Other laboratory results
3.4.1. Sensitivities to other antibiotics
Sensitivities to a selection of anti-staphylococcal antibiotics
were available from routine automated testing. Only three (2%)
Table 3
Frequency distributions of MICs of all saved isolates to various antibiotics
MIC (mg/l)
0.05 0.09 0.13 0.19 0.25 0.38 0.5 0.75 1 1.5
Vancomycin 4 25 59 23 28 3
Linezolid 7 8 55 43 25 4
Daptomycin 4 6 27 32 46 21 6
Tigecycline 28 43 59 8 3 1
MIC, minimum inhibitory concentration.
All isolates had MICs below accepted sensitivity breakpoints for each antibiotic. Bold font shows modal MIC for each antibiotic.
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associated with community-onset infection. Most isolates were
sensitive to gentamicin (181 episodes; 93%), rifampin (180
episodes; 92%), fusidic acid (182 episodes; 93%), and tetracycline
(185 episodes; 95%).
Isolates could be recovered from 142 episodes (73%) for MIC
determination. There was no difference in patient characteristics
between episodes with available isolates and those where the
isolate was unavailable (data not shown). All isolates were
sensitive to vancomycin, linezolid, daptomycin, and tigecycline
according to standard criteria (Table 3).10,11
The vancomycin MIC ranged from 0.25 mg/l to 1.5 mg/l, with a
median of 0.5 mg/l. Fifty-four of 142 (38%) isolates had a
vancomycin MIC above 0.5 mg/l. There was no signiﬁcant
difference in mortality rate or subsequent relapse rate between
these episodes and episodeswhere the isolates had aMIC0.5 mg/
l (data not shown). We looked for evidence of ‘MIC creep’ from
2006 through 2007, with no obvious shift in the distribution being
observed over this period (data not shown). We did not detect
vancomycin heteroresistance in any of the isolates. We also tested
MRSA isolates from later in the clinical course of the two patients
with ongoing bacteremia. We did not detect hVISA, or any rise in
MIC, in any of these later isolates.
3.4.2. SCCmec typing
We analyzed the SCCmec types of 82 randomly chosen isolates.
SCCmec type IV was detected in 72 (88%) isolates, SCCmec type II in
seven isolates (9%), and three isolates (4%) were untypeable.
Subtyping of a selection of 35 isolates with SCCmec type IV showed
33 (94%) were subtype IVh and two were subtype IVd.
4. Discussion
In comparison with a previous study from this institution, the
incidence of MRSA bacteremia has fallen from approximately 37/
10000 admissions to 16/10 000 admissions.12 This is in linewith the
secular trend in the UK, and probably reﬂects improvements in
infection controlmeasures. Similar to previous reports, community-
associatedMRSA bacteremia remains uncommon.13,14 Patientswho
developed MRSA bacteremia within 48 h of hospital admission had
usually had signiﬁcant contact with secondary healthcare in the
preceding 12 months. We showed a continuing high mortality, as
previously reported.12,15Wenoted that a history of a negativeMRSA
screenorabsenceofprior isolationofMRSA inasepticpatient isnota
reliable indicator in ruling out MRSA as the cause of sepsis.
IVDs remain the predominant source of infection. Our incidence
of endocarditis (3%) is lower than previous reports.16,17,18 This may
be an underestimation as we do not routinely undertake
echocardiography in cases of MRSA bacteremia (see methods).
Although echocardiography was recommended in all cases where
there was no identiﬁable focus of infection, it was often difﬁcult to
persuade clinicians of the clinical utility of a TEE in the absence of
clinical signs of endocarditis and after a normal TTE, despite the
reported high incidence of endocarditis in these patients.We found no convincing evidence that pneumonia was the
focus for any of the episodes of MRSA bacteremia, and would agree
with others that pneumonia tends to be over-diagnosed as a focus
for S. aureus bacteremia, with most respiratory isolates reﬂecting
colonization of the upper respiratory tract.19 The highest mortality
was found in patients without an identiﬁable focus, as has been
previously described.20 In our study, patients without an identiﬁ-
able focus of infection tended to be treated in a similarway to those
with a probable IVD focus, in terms of duration and dosage of
antibiotics (data not shown). Short courses of antibiotics may not
be adequate if there is an unidentiﬁed deep source of infection,
such as endocarditis.
Although a delay in starting an antibiotic active against S. aureus
has been found not to be an important predictor of mortality in S.
aureus bacteremia in some studies,21,22 others have shown that
timely empirical therapy for S. aureus bacteremia is associated
with reducedmortality.23,24 One of the reasons for this discrepancy
may be that delays in empirical therapy have most impact in
severely unwell patients.24 In our study, in patients with MRSA
bacteremia who had signs of severe sepsis, a delay in starting an
antibiotic active against MRSA was associated with a higher
mortality. Conversely, in patients who did not have hemodynamic
instability, such an interactionwas not seen. It is noteworthy that a
signiﬁcant number of patients (21%) had had a negative MRSA
screen in the preceding 3 months. Therefore, empirical antibiotic
therapy against MRSA needs to be considered not only for patients
known to have been colonized with MRSA, but also for any patient
with serious sepsis of unknown cause, especially if there has been
recent contact with healthcare facilities. In patients who are not
hemodynamically unstable, it may be appropriate to await
microbiological results to guide the choice of antimicrobial agent.
Similar to the ﬁndings of a surveillance study of MRSA isolates
from the UK and Ireland, all isolates were sensitive to vancomycin,
linezolid, daptomycin, and tigecycline.25 We did not detect
vancomycin heteroresistance, similar to a recent study from
another UK hospital,26 but in contrast to studies from other
countries.27,28 This was surprising, given that vancomycin is used
widely throughout our institution. Serial passage over several days
has been shown to lead to a reduction in the detection of
glycopeptide resistance,29 and it is possible that heteroresistance
had been lost in our recovered isolates. We did not carry out a
population analysis proﬁle–area under the curve ratio (PAP–AUC)
analysis to determine the presence of vancomycin heteroresis-
tance, but the macro E-test has been shown to have a sensitivity of
approximately 90% in the detection of heteroresistance.4,28 The
incidence of glycopeptide resistance may vary signiﬁcantly
between institutions and such changes in resistance phenotypes
should be subject to local surveillance.
Unlike previous reports, we did not observe any adverse
outcome associated with isolates with vancomycin MICs above
0.5 mg/l.30 Our study was not designed to detect complications
that were not microbiologically deﬁned, or that occurred after
transfer or readmission to other institutions, and this may have
resulted in a falsely low complication rate. Also, we did not analyze
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course of treatment due to perceived failure of vancomycin
therapy. It is also possible that differences in the genetic
background of MRSA from the UK and elsewhere have an impact
on outcome. Subtyping of the SCCmec gene showed that subtype
IVh was most common in our institution. This corresponds with
the EMRSA15 lineage prevalent in UK hospital settings,31 and is a
similar ﬁnding to that of a previous study which showed 84/130
isolates to be type IV.12
In conclusion, our results support prompt initiation of
antibiotics targeted against MRSA in cases of MRSA bacteremia,
especially in patients with signs of severe sepsis, and encourage
thorough investigation to identify the focus of infection. In cases
where the focus of infection is not identiﬁable, it may be
appropriate to consider longer courses of antibiotics. A previous
negative MRSA screen or absence of previous isolation of MRSA
from clinical specimens should not be relied on to withhold
empirical cover against MRSA in a septic patient. We found no
evidence of reduced susceptibility to vancomycin in our isolates
and, as with other mechanisms of antibiotic resistance, the
emergence of vancomycin resistance should be regularly moni-
tored at a local level. Research on other factors, such as tolerance of
MRSA isolates to glycopeptides and virulence factors, may help in
improving management of these serious infections. In the
meantime in cases of failure of vancomycin therapy, after control
of source of infection, alternative agents with activity against
MRSA may be considered.
Conﬂict of interest
No conﬂict of interest declared.
Acknowledgements
We would like to thank Dr J. Rollason, Department of
Microbiology, Aston University, Birmingham, UK for help with
SCCmec typing and Dr A. Lovering, Antimicrobial Reference
Laboratory, Bristol, UK for providing the control hVISA strains.
References
1. UK Health Protection Agency. Health protection report: Quarterly MRSA bac-
teraemia data (September to December, 2008) derived from mandatory sur-
veillance, March 2009. Available at: http://www.hpa.org.uk/hpr/archives/
2009/news1109.htm#mrsa (accessed July 17, 2009).
2. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al.
Relationship between vancomycin MIC and failure among patients with meth-
icillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.
Antimicrob Agents Chemother 2008;52:3315–20.
3. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al.
Comparison of community- and health care-associated methicillin-resistant
Staphylococcus aureus infection. JAMA 2003;290:2976–84.
4. WoottonM,MacGowan AP,Walsh TR, Howe RA. Amulticenter study evaluating
the current strategies for isolating Staphylococcus aureus strains with reduced
susceptibility to glycopeptides. J Clin Microbiol 2007;45:329–32.
5. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, DaumRS, Labischinski H, Hiramatsu
K. Activated cell-wall synthesis is associated with vancomycin resistance in
methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J
Antimicrob Chemother 1998;42:199–209.
6. Milheiric¸o C, Oliveira D, Lencastre H. Update to the multiplex PCR strategy for
assignment of mec element types in Staphylococcus aureus. Antimicrob Agents
Chemother 2007;51:3374–7.
7. Milheiric¸o C, Oliveira D, Lencastre H. Multiplex PCR strategy for subtyping the
staphylococcal cassette chromosome mec type IV in methicillin-resistant Staph-
ylococcus aureus: ‘SCCmec IV multiplex’. J Antimicrob Chemother 2007;60:42–8.
8. Maki DG, Weise CE, Sarafoin HW. A semi-quantitative culture method for identi-
fying intravenous-catheter-related infection. N Engl J Med 1977;296:1305–9.9. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endo-
carditis: utilization of speciﬁc echocardiographic ﬁndings. Am J Med
1994;96:200–9.
10. Andrews JM; on behalf of the BSAC Working Party on Susceptibility Testing.
BSAC standardized disc susceptibility testing method (version 6.1). Available
at: http://www.bsac.org.uk/Resources/BSAC/version_6.1.pdf (accessed Decem-
ber 4, 2008).
11. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial
susceptibility tests for bacteria that grow aerobically. 7th ed. Approved stan-
dard. Document M7-A7. Wayne, PA: CLSI; 2006.
12. Das I, O’Connell N, Lambert P. Epidemiology, clinical and laboratory character-
istics of Staphylococcus aureus bacteraemia in a university hospital in UK. J Hosp
Infect 2007;65:117–23.
13. Klevens RM, Morrison MA, Nadle J. Invasive methicillin-resistant Staphylococ-
cus aureus infections in the United States. JAMA 2007;298:1763–71.
14. Miller R, Esmail H, Peto T, Walker S, Crook D, Wyllie D. Is MRSA admission
bacteraemia community-acquired? A case control study. J Infect 2008;56:163–
70.
15. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli
Y. Comparison of mortality associated with methicillin-resistant and methicil-
lin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect
Dis 2003;36:53–9.
16. Fowler Jr VG, Li J, Corey GR, Boley J, Marr KA, Gopal AK, et al. Role of
echocardiography in evaluation of patients with Staphylococcus aureus bacter-
emia: experience in 103 patients. J Am Coll Cardiol 1997;30:1072–8.
17. Chang FY, MacDonald BB, Peacock Jr JE, Musher DM, Triplett P, Mylotte JM, et al.
A prospectivemulticenter study of Staphylococcus aureus bacteremia: incidence
of endocarditis, risk factors for mortality, and clinical impact of methicillin
resistance. Medicine (Baltimore) 2003;82:322–32.
18. Van Hal SJ, Mathur G, Kelly J, Aronis C, Cranney GB, Jones PD. The role of
transthoracic echocardiography in excluding left sided infective endocarditis in
Staphylococcus aureus bacteraemia. J Infect 2005;51:218–21.
19. Sakaguchi M, Shime N, Fujita N, Fujiki S, Hashimoto S. Current problems in the
diagnosis and treatment of hospital-acquiredmethicillin-resistant Staphylococ-
cus aureus pneumonia. J Anesth 2008;22:125–30.
20. Hill PC, Birch M, Chambers S, Drinkovic D, Ellis-Pegler RB, Everts R, et al.
Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determi-
nation of factors affecting incidence and mortality. Intern Med J 2001;31:97–
103.
21. Fang CT, Shau WY, Hsueh PR, Chen YC, Wang JT, Hung CC, et al. Early empirical
glycopeptide therapy for patients with methicillin-resistant Staphylococcus
aureus bacteraemia: impact on the outcome. J Antimicrob Chemother
2006;57:511–9.
22. Kim SH, Park WB, Lee CS, Kang CI, Bang JW, Kim HB, et al. Outcome of
inappropriate empirical antibiotic therapy in patients with Staphylococcus
aureus bacteraemia: analytical strategy using propensity scores. Clin Microbiol
Infect 2006;12:13–21.
23. Go´mez J, Garcı´a-Va´zquez E, Ban˜os R, CanterasM, Ruiz J, Ban˜os V, et al. Predictors
of mortality in patients with methicillin-resistant Staphylococcus aureus
(MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur J Clin Microbiol
Infect Dis 2007;26:239–45.
24. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed
antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia.
Clin Infect Dis 2003;36:1418–23.
25. Hope R, Livermore DM, Brick G, Lillie M, Reynolds R, BSAC Working Parties on
Resistance Surveillance. Non-susceptibility trends among staphylococci from
bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother
2008;62(Suppl 2):ii65–72.
26. Beeston CJ, Gupta R, Chadwick PR, Young RJ. Methicillin-resistant Staphylococ-
cus aureus bacteraemia and mortality in a teaching hospital. Eur J Clin Microbiol
Infect Dis 2009;28:585–90.
27. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features
associated with bacteremia due to heterogeneous vancomycin-intermediate
Staphylococcus aureus. Clin Infect Dis 2004;38:448–51.
28. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characteriza-
tion of vancomycin-heteroresistant Staphylococcus aureus from the metropoli-
tan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin
Microbiol 2008;46:2950–4.
29. Boyle-Vavra S, Berke SK, Lee JC, Daum RS. Reversion of the glycopeptide
resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob
Agents Chemother 2000;44:272–7.
30. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering Jr RC, Eliopoulos
GM. Relationship of MIC and bactericidal activity to efﬁcacy of vancomycin for
treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin
Microbiol 2004;42:2398–402.
31. Caddick JM, Hilton AC, Rollason J, Lambert PA, Worthington T, Elliott TS.
Molecular analysis of methicillin-resistant Staphylococcus aureus reveals an
absence of plasmid DNA in multidrug-resistant isolates. FEMS Immunol Med
Microbiol 2005;44:297–302.
